● pepmg Research Desk · Peer-reviewed evidence review
What the research says about retatrutide
A neutral summary of the peer-reviewed literature on retatrutide, an experimental triple-hormone-receptor agonist studied in early-phase human trials for obesity. Research use only.
Moderate evidence — Limited human trials — often early-phase. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Retatrutide is an experimental agonist of the GIP, GLP-1, and glucagon receptors that has been studied in early-phase human trials for obesity and related metabolic conditions [1][2].
- The largest published human data is a phase 2, randomized, placebo-controlled trial; as of this review no phase 3 results or regulatory approvals exist [1].
- This page summarizes what those studies measured and links to each one — it is not medical advice, an efficacy or safety claim, or dosing guidance.
What retatrutide is
Retatrutide (also written LY3437943) is described in the literature as an agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors [1]. It sits in the same broad research area as other incretin-based compounds pepmg tracks, but with an added glucagon-receptor action.
The phase 2 trial authors noted at the outset that retatrutide's dose-response relationships for side effects, safety, and efficacy in obesity were not known — i.e. these were open research questions the trial set out to measure, not settled facts [1].
What the human research has measured
Moderate evidenceThe main published human study is a phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity (or overweight plus a weight-related condition), run over 48 weeks with a primary endpoint of percentage change in body weight at 24 weeks [1].
The trial reported least-squares mean body-weight changes at 48 weeks of roughly −8.7% to −24.2% across the retatrutide groups versus about −2.1% in the placebo group; the most common adverse events reported were gastrointestinal, described as dose-related and mostly mild to moderate [1]. These are trial measurements in a research setting, not evidence of real-world benefit or safety.
A separate phase 2a trial examined retatrutide in metabolic dysfunction-associated steatotic liver disease [2], and a systematic review and meta-analysis has since pooled retatrutide randomized-trial data on weight and metabolic markers [3]. Together these are early-phase human studies — informative, but far short of the multi-trial phase 3 base that established, approved medicines rest on.
How strong is the evidence
Human randomized data exists, which is why this review is characterized as moderate rather than preclinical — but it is early-phase (phase 2), the sample sizes are modest, and there is no phase 3 program or regulatory approval reflected in this literature [1][2][3].
Nothing here says retatrutide works, is safe, or is appropriate for human use. It is sold by third parties for laboratory and research use only. Read the studies themselves and consult a qualified professional — this page is a map to the evidence, not a recommendation.
Sources · 3
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.